Psomagen, Inc. Logo

Psomagen, Inc.

A contract lab providing multiomics and data analysis solutions for researchers.

950200 | KO

Overview

Corporate Details

ISIN(s):
KR8840150005
LEI:
Country:
United States of America
Address:
City of Wilmington, County of New Castle, State of Delaware, Corporation Trust Cen, Wilmington

Description

Psomagen, Inc. is a contract laboratory service provider specializing in multiomics and data analysis solutions for scientists and clinicians. Operating from CLIA-certified and CAP-accredited facilities, the company offers a comprehensive suite of services to the academic, clinical, and life sciences research communities. Its core offerings encompass genomics, epigenomics, proteomics, transcriptomics, and metagenomics. Psomagen utilizes a range of sequencing technologies, including Sanger sequencing, Next-Generation Sequencing (NGS), and third-generation sequencing. The company also provides specialized solutions such as spatial biology analysis, cell line authentication via STR profiling, and advanced bioinformatics support to analyze complex biological data.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2023-03-23 00:00
사업보고서 (2022.12)
Korean 1.5 MB
2023-03-23 00:00
[기재정정]주주총회소집공고
Korean 421.9 KB
2023-03-16 00:00
주주총회소집공고
Korean 345.9 KB
2023-03-03 00:00
주주총회소집결의
Korean 16.9 KB
2023-03-03 00:00
주주총회집중일개최사유신고
Korean 5.3 KB
2023-03-03 00:00
의결권대리행사권유참고서류
Korean 308.3 KB
2023-02-16 00:00
매출액또는손익구조30%(대규모법인은15%)이상변동
Korean 13.5 KB
2023-01-10 00:00
단일판매ㆍ공급계약체결(자율공시)
Korean 9.8 KB
2022-12-16 00:00
기타경영사항(자율공시)(제19기 정기주주총회 권리주주 확정을 위한 증권예탁증권 기준일 설정 공고)
Korean 4.5 KB
2022-12-09 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.7 KB
2022-12-09 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.7 KB
2022-11-14 00:00
분기보고서 (2022.09)
Korean 1.1 MB
2022-11-11 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.3 KB
2022-11-04 00:00
[기재정정]주식매수선택권부여에관한신고
Korean 30.2 KB
2022-10-26 00:00
기업설명회(IR)개최
Korean 6.8 KB

Automate Your Workflow. Get a real-time feed of all Psomagen, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Psomagen, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Psomagen, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.